Trials / Completed
CompletedNCT00255021
Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 186 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 2 Months – 2 Months
- Healthy volunteers
- Accepted
Summary
The present clinical study will assess the immunogenicity and reactogenicity of Sanofi Pasteur's DTacP-IPV// PRP\~T combined vaccine (Pentavac™ or Pentaxim™) as a three-dose primary vaccination at 2, 4, and 6 months of age followed by a booster dose during the second year of life and concomitant hepatitis B vaccine at 2 and 6 months of age in infants in Thailand.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac | 0.5 mL, IM |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2007-09-01
- Completion
- 2009-01-01
- First posted
- 2005-11-17
- Last updated
- 2012-04-16
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT00255021. Inclusion in this directory is not an endorsement.